2024-12-01 2025-11-30 false Capium Accounts Production 1.1 09856553 2024-12-01 2025-11-30 09856553 bus:AbridgedAccounts 2024-12-01 2025-11-30 09856553 bus:FRS102 2024-12-01 2025-11-30 09856553 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 09856553 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 09856553 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 09856553 2024-12-01 2025-11-30 09856553 2025-11-30 09856553 bus:RegisteredOffice 2024-12-01 2025-11-30 09856553 core:WithinOneYear 2025-11-30 09856553 core:AfterOneYear 2025-11-30 09856553 1 2024-12-01 2025-11-30 09856553 bus:Director1 2024-12-01 2025-11-30 09856553 bus:Director1 2025-11-30 09856553 bus:Director1 2023-12-01 2024-11-30 09856553 2023-12-01 09856553 bus:LeadAgentIfApplicable 2024-12-01 2025-11-30 09856553 2023-12-01 2024-11-30 09856553 2024-11-30 09856553 core:WithinOneYear 2024-11-30 09856553 core:AfterOneYear 2024-11-30 09856553 bus:EntityAccountantsOrAuditors 2023-12-01 2024-11-30 09856553 core:LandBuildings 2024-12-01 2025-11-30 09856553 core:LandBuildings 2025-11-30 09856553 core:LandBuildings 2024-11-30 09856553 core:FurnitureFittings 2024-12-01 2025-11-30 09856553 core:FurnitureFittings 2025-11-30 09856553 core:FurnitureFittings 2024-11-30 09856553 core:ComputerEquipment 2024-12-01 2025-11-30 09856553 core:ComputerEquipment 2025-11-30 09856553 core:ComputerEquipment 2024-11-30 09856553 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-11-30 09856553 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-11-30 09856553 core:NetGoodwill 2024-12-01 2025-11-30 09856553 core:NetGoodwill 2025-11-30 09856553 core:NetGoodwill 2024-11-30 09856553 core:CostValuation core:Non-currentFinancialInstruments 2025-11-30 09856553 core:CostValuation core:Non-currentFinancialInstruments 2024-11-30 09856553 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-11-30 09856553 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-11-30 09856553 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-11-30 09856553 core:Non-currentFinancialInstruments 2025-11-30 09856553 core:Non-currentFinancialInstruments 2024-11-30 09856553 core:ShareCapital 2025-11-30 09856553 core:ShareCapital 2024-11-30 09856553 core:RetainedEarningsAccumulatedLosses 2025-11-30 09856553 core:RetainedEarningsAccumulatedLosses 2024-11-30 09856553 dpl:Item1 2024-12-01 09856553 dpl:Item1 2025-11-30 09856553 dpl:Item1 2023-12-01 09856553 dpl:Item1 2024-11-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 09856553
England and Wales

 

 

 

ALPHADRUGS LIMITED



Abridged Accounts
 


Period of accounts

Start date: 01 December 2024

End date: 30 November 2025
Report to the directors on the preparation of the unaudited statutory accounts of Alphadrugs Limited for the year ended 30 November 2025.
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Alphadrugs Limited for the year ended 30 November 2025 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/.
This report is made solely to the Board of Directors of Alphadrugs Limited, as a body, in accordance with the terms of our engagement letter dated 27 August 2026. Our work has been undertaken solely to prepare for your approval the accounts of Alphadrugs Limited and state those matters that we have agreed to state to the Board of Directors of Alphadrugs Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Alphadrugs Limited and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that Alphadrugs Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Alphadrugs Limited. You consider that Alphadrugs Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of Alphadrugs Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
30 November 2025.



....................................................
Martin Morrison & Co Limited
Unit 43 The Coach House
66-70 Bourne Road
Bexley
DA5 1LU
27 August 2026
1
 
 
Notes
 
2025
£
  2024
£
Fixed assets      
Intangible fixed assets 3 175,815    193,396 
Tangible fixed assets 4 1    10,000 
175,816    203,396 
Current assets      
Stocks 14,959    15,617 
Debtors 30,439    21,350 
Cash at bank and in hand 7,397    2,707 
52,795    39,674 
Creditors: amount falling due within one year (77,263)   (65,570)
Net current assets (24,468)   (25,896)
 
Total assets less current liabilities 151,348    177,500 
Creditors: amount falling due after more than one year (189,318)   (217,416)
Net assets (37,970)   (39,916)
 

Capital and reserves
     
Called up share capital 100    100 
Profit and loss account (38,070)   (40,016)
Shareholders' funds (37,970)   (39,916)
 


For the year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006 the profit and loss account has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 27 August 2026 and were signed by:


-------------------------------
Adewale Samuel Anigilaje
Director
2
General Information
Alphadrugs Limited is a private company, limited by shares, registered in England and Wales, registration number 09856553, registration address 29 High Street, Kimbolton, Huntingdon, Cambridgeshire, PE28 0HB.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Goodwill
Acquired goodwill is stated at cost less amortisation. Amortisation is calculated on a straight line basis over the estimated expected useful economic life of the goodwill of [20] years.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 25% Straight Line
Fixtures and Fittings 25% Straight Line
Land and Buildings 10 Reducing Balance
Stocks
Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.
2.

Average number of employees

Average number of employees during the year was 2 (2024 : 3).
3.

Intangible fixed assets

Cost Goodwill   Total
  £   £
At 01 December 2024 351,627    351,627 
Additions  
Disposals  
At 30 November 2025 351,627    351,627 
Amortisation
At 01 December 2024 158,231    158,231 
Charge for year 17,581    17,581 
On disposals  
At 30 November 2025 175,812    175,812 
Net book values
At 30 November 2025 175,815    175,815 
At 30 November 2024 193,396    193,396 


4.

Tangible fixed assets

Cost or valuation Land and Buildings   Fixtures and Fittings   Computer Equipment   Total
  £   £   £   £
At 01 December 2024 100,000    10,251    660    110,911 
Additions      
Disposals      
At 30 November 2025 100,000    10,251    660    110,911 
Depreciation
At 01 December 2024 90,000    10,252    659    100,911 
Charge for year 9,999        9,999 
On disposals      
At 30 November 2025 99,999    10,252    659    110,910 
Net book values
Closing balance as at 30 November 2025 1    (1)   1    1 
Opening balance as at 01 December 2024 10,000    (1)   1    10,000 


3